Hester Biosciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Hester Biosciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 25% in 3 years; of every extra ₹100 of sales, ₹44 became extra profit. Higher than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹173Over the last 3 years, every ₹100 of reported profit came with ₹173 of operating cash.
Higher than 81% of Healthcare companies in India.
Self-Funding Ratio
2.8×Over the last 3 years its own operating cash covered its investment spending (capex) 2.8 times.
Higher than 79% of Healthcare companies in India.
Cash Locked Ratio
₹38For every ₹100 of sales, ₹38 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹44 tied up three years earlier.
More money tied up than 73% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹44Sales grew 25% in 3 years; of every extra ₹100 of sales, ₹44 became extra profit.
Higher than 90% of Healthcare companies in India.
Asset Productivity Ratio
+25% / +1%In 3 years sales changed by +25% while total assets changed by +1%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.7×Debt due within a year is covered 0.7 times by its yearly operating cash.
Lower than 65% of Healthcare companies in India.
Cash Cushion Ratio
−11%Debt, after subtracting cash, equals 11% of its market value (net debt).
Lower than 80% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 57% of Healthcare companies in India.
Tangible Net Worth Ratio
97%Of every ₹100 of net worth, ₹97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 54% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Hester Biosciences Limited owes ₹0.46 for every ₹1 it owns. Net profit rose 102% in the year to Mar 2026, and grew 28% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
12.8Investors pay ₹12.8 for every ₹1 of Hester Biosciences Limited's yearly profit, lower than 91% of Healthcare companies in India.
P/B ratio
5.07The share price is 5.07 times Hester Biosciences Limited's book value per share, higher than 55% of Healthcare companies in India.
Market cap
₹1,826 CrThe total market value of all of Hester Biosciences Limited's shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹360 CrWhat Hester Biosciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹423.46Net worth divided by the number of shares. The share price of ₹2,147 is 5.1 times this, which is the P/B above.
Return on equity (ROE)
39.7%Hester Biosciences Limited earned 39.7% on its shareholders' money over the last year, higher than 96% of Healthcare companies in India.
Owes vs Owns
0.46×Hester Biosciences Limited owes ₹0.46 for every ₹1 it owns (low), higher than 74% of Healthcare companies in India.
Dividend yield
0.51%Hester Biosciences Limited pays 0.51% of its share price as dividends a year, higher than 64% of dividend-paying Healthcare companies in India.
Revenue growth
+7%Revenue rose 7% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
+102%Net profit rose 102% in the year to Mar 2026, and grew 28% a year on average over 3 years.
Profit margin
16.7%Hester Biosciences Limited keeps ₹17 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from Hester Biosciences Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
10.4×Hester Biosciences Limited's operating profit covered its interest costs 10.4 times in the year to Mar 2026.
Cash vs debt
Net debtHester Biosciences Limited had ₹192 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Hester Biosciences Limited's P/E ratio?
Investors pay ₹12.8 for every ₹1 of Hester Biosciences Limited's yearly profit, lower than 91% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Hester Biosciences Limited: ₹1,826 Cr ÷ ₹360 Cr (31 Mar 2026) = 5.1.
What is Hester Biosciences Limited's return on equity?
Hester Biosciences Limited earned 39.7% on its shareholders' money over the last year, higher than 96% of Healthcare companies in India.
How much does Hester Biosciences Limited owe compared with what it owns?
Hester Biosciences Limited owes ₹0.46 for every ₹1 it owns (low), higher than 74% of Healthcare companies in India.
Does Hester Biosciences Limited pay a dividend?
Yes. Hester Biosciences Limited pays 0.51% of its share price as dividends a year, higher than 64% of dividend-paying Healthcare companies in India.
Is Hester Biosciences Limited's revenue growing?
Revenue rose 7% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.